Company
Headquarters: West Perth, WA, Australia
A$17.6 Million
AUD as of Jan. 1, 2024
US$12.0 Million
Company | Market Cap (USD) |
---|---|
Zoetis Inc. | $89.09 B |
MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
Takeda Pharmaceutical Company Limited | $47.71 B |
Haleon plc | $38.90 B |
PPD, Inc. | $16.58 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
AusCann Group Holdings Ltd researches, develops, and commercializes various cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. It offers tetrahydrocannabinol and cannabidiol powder-based hard-shell capsules using Neuvis technology platform for the treatment of pain and related indications; CPAT-01, a liquid, oral veterinary medicine to treat pain and inflammation in dogs; and DermaCann, a liquid oral oil formulation containing CBD for healthy skin and immune function in dogs. The company is headquartered in West Perth, Australia.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
AusCann Group Holdings Ltd has the following listings and related stock indices.
Stock: ASX: AC8 wb_incandescent
Stock: FSX: UVP wb_incandescent